Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT00516503

Organisation Name: Alliance for Clinical Trials in Oncology

Overal Status: Completed

Start Date: February 2008

Last Update: August 24, 2017

Lead Sponsor: Alliance for Clinical Trials in Oncology

Brief Summary: RATIONALE: Baclofen-amitriptyline-ketamine (BAK) gel may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether BAK gel is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy .

PURPOSE: This randomized phase III trial is studying BAK gel to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.

Conditions:
  • Chronic Myeloproliferative Disorders
  • Leukemia
  • Lymphoma
  • Lymphoproliferative Disorder
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Neurotoxicity
  • Pain
  • Unspecified Adult Solid Tumor, Protocol Specific


Total execution time in seconds: 0.29625988006592